42 U.S.C. § 287: National Center for Advancing Translational Sciences

coordinating and developing resources that leverage basic research in support of translational science; and developing partnerships and working cooperatively to foster synergy in ways that do not create duplication, redundancy, and competition with industry activities. The Center may develop and provide infrastructure and resources for all phases of clinical trials research. Except as provided in paragraph (2), the Center may support clinical trials only through the end of phase IIB. the Center gives public notice for a period of at least 120 days of the Center’s intention to support the clinical trial activities in phase III; no public or private organization provides credible written intent to the Center that the organization has timely plans to further the clinical trial activities or conduct clinical trials of a similar nature beyond phase IIB; and the Center ensures that support of the clinical trial activities in phase III will not increase the Federal Government’s liability beyond the award value of the Center’s support. the molecules being studied; clinical trial activities being conducted; the methods and tools in development; the rationale for each partnership; the status of each partnership; the funding provided by the Center to other entities pursuant to each partnership, and the activities which have been transferred to industry pursuant to each partnership; known research activity of other entities that is or will expand upon research activity of the Center; the methods and tools, if any, that have been developed since the last biennial report was prepared; and the methods and tools, if any, that have been developed and are being utilized by the Food and Drug Administration to support medical product reviews. The first biennial report submitted under this section after December 13, 2016 , shall include a complete list of all of the methods and tools, if any, which have been developed by research supported by the Center. Nothing in this section shall be construed as authorizing the Secretary to disclose any information that is a trade secret, or other privileged or confidential information subject to section 552(b)(4) of title 5 or section 1905 of title 18 .